Use of antiretroviral drugs to prevent sexual transmission of HIV

Current Clinical Topics in Infectious Diseases

Volumn , Issue 22, 2002, Pages 214-251

  Cohen, Myron S ^a   Hosseinipour, Mina ^a   Kashuba, Angela ^a   Butera, Salvatore ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANIMAL; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; BLOOD TRANSFUSION; DISEASE TRANSMISSION; DRUG EFFECT; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NEWBORN; PREGNANCY; PRIMATE; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; VIROLOGY; VIRUS LOAD; VIRUS SHEDDING;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD TRANSFUSION; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; MALE; MODELS, ANIMAL; PREGNANCY; PRIMATES; RISK FACTORS; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASES, VIRAL; VIRAL LOAD; VIRUS SHEDDING;

EID: 0036981570     PISSN: 01953842     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (164)

1. Sepkowitz K. AIDS-the first 20 years. N Engl J Med 2001;344:1764-1772.
2. CDC. HIV and AIDS-United States 1981-2000. MMWR 2001;50;430-434.
3. Joint United Nations Program on HIV/AIDS. Report on the HIV/AIDS global epidemic - June 2000. Geneva, Switzerland: Joint United Nations Program on HIV/AIDS, 2000;UNAIDS /00.13E.
4. Cohen MS, Dallabetta G, Holmes KK, Cates W. Global Prevention of HIV Transmission. In:The Medical Management of AIDS. WB Saunders Company, 1999:499-512.
5. Kamali A, Carpenter LM, Whitworth JAG, et al. Seven year trends in HIV-1 infection rates, and changes in sexual behavior, among adults in rural Uganda. AIDS 2000;14:427-34.
6. Kilmarx PH, Supawitkul S, Wankrairoj M, et al. Explosive spread and effective control of human immunodeficiency virus in northernmost Thailand: the epidemic in Chiang Rai province, 1988-99. AIDS 2000;14:2731-2740.
7. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomized controlled trial. Lancet 1995;346: 530-536.
8. Royce RA, Seña A, Cates WJ, Cohen MS. Sexual Transmission of HIV. N Engl J Med 1997;336:1072-1078.
9. Vernazza PL, Eron JJ, Fiscus SA, Cohen MS. Sexual transmission of HIV: infectiousness and prevention. AIDS 1999;13:155-166.
10. Chakraborty H, Helms RW, Sen PK, Cohen MS. Estimating correlation by using a general linear mixed model: evaluation of the relationship between the concentration of HIV-1 RNA in blood and semen. Submitted, Stat. Med. 2001.
11. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000;14:415-421.
12. Lampinen TM, Critchlow CW, Kuypers JM, et al. Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men. AIDS 2000;14:F69-F75.
13. Shugars DC, Slade GD, Patton LL, Fiscus SA. Oral and systemic factors associated with increased levels of human immunodeficiency virus type 1 RNA in saliva. Oral Surg, Oral Med, Oral Pathol Oral Radiol Endod 2000;89:432-440.
14. Kiessling AA, Fitzgerald LM, Zhang D, et al. Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir. AIDS Res Hum Retroviruses 1998;14(suppl 1):S33-S41.
15. Delwart EL, Mullins JI, Gupta P, et al. Human immunodeficiency virus type 1 populations in blood and semen. J Virol 1998;72: 617-623.
16. Ellerbrock TV, Lennox JL, Claney KA, et al. Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis 2001;184:28-36.
17. Ping LH, Nelson JAE, Hoffman IF, et al. Characterization of V3 sequence heterogeneity in subtype C HIV-1 isolates from Malawi: underrepresentation of X4 variants. J Virol 1998; 73:6271-6281.
18. Ping LH, Cohen MS, Hoffman IF, et al. Effects of Genital Tract inflammation on human immunodeficiency virus type 1 V3 populations in blood an semen. J Virol 2000; 74:8946-8952.
19. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921-929.
20. Gray RH, Wawer MJ, Brookmeyer R, et al. Rakai Project Team. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357:1149-1153.
21. Chakraborty H, Sen PK, Helms RW, et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS 2001;15: 621-627.
22. Mastro TD, Satten GA, Nopkesom T, et al. Probability of female-to-male transmission of HIV-1 in Thailand [see comments]. Lancet 1994;343:204-207.
23. Tovanabutra S, Robison V, Wongtrakul J, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J AIDS 2002;29(3):275-283.
24. Dyer JR, Kazembe P, Vemazza PL, et al. High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis 1998;177:1742-1746.
25. Schuitemaker H, Koot M, Kootstra NA, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992;66(3):1354-1356.
26. Wainberg MA, Friedland G. Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance. JAMA 1998;279:1977-1983.
27. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing continuating combination antiretroviraldrug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2000; 344:472-480.
28. Sodora DL, Gettie A, Miller CJ, Marx PA. Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Research & Human Retroviruses 1998;(14 suppl):S119-S123.
29. DePasquale MP, Rosenberg E, Quayle A, et al. Primary HIV infection: in vivo fitness of pre-therapy resistant mutants and potential for secondary spread of HIV from semen. Abstract 126. Third International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, CA June 1999; Antiviral Therapy 1999; 4(suppl 1):89.
30. DePasquale MP, Rosenberg E, Quayle A, et al. Primary HIV infection: in vivo fitness of pre-therapy resistant mutants and potential for secondary spread of HIV from semen. Abstract 126. Third International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, CA June 1999; Antiviral Therapy 1999; 4(suppl 1):89.
31. Spira AI, Patterson BK, Gettie A, et al. Identification of the infected target cell in the mucosa and kinetics of viral spread following intravaginal inoculation of sivmac251 into Rhesus macaques. Keystone, CO: Keystone Symposia on Molecular & Cellular Biology, HIV Pathogenesis, 1995.
32. Stahl-Hennig C, Steinman RM, Tenner-Racz K, et al. Rapid infection of oral mucosalassociated lymphoid tissue with simian immunodeficiency virus. Science 1999;285:1261-1265.
33. Patterson BK, Landay A, Andersson J, et al. Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am Journ Pathol 1998;153:481-490.
34. Patterson BK, Bailey RC, Siegel J, et al. Biologic mechanisms of HIV infection of human foreskin: implications for transmission. Am J Path 2001; Submitted.
35. Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and metaanalysis. AIDS 2000;14:2361-2370.
36. Bjorndal A, Deng H, Jansson M, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997;71:7478-7487.
37. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382: 722-725.
38. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377.
39. Klebanoff SJ, Coombs RW. Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. J Exp Med 1991;174:289-292.
40. Taha TE, Hoover DR, Dallabetta GA, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 1998;12:1699-1706.
41. Patterson BK, Landay A, Anderson J, et al. Repertoire of chemokine receptor expression in the female genital tract. Am J Pathog 1998;153: 481-490.
42. Fowke KR, Nagelkerke NJD, Kimani J, et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996;348:1347-1351.
43. Kaul R, Trabattoni D, Bwayo JJ, et al. HIV-1 specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 1999;13: 23-29.
44. Rowland-Jones SL, Dong T, Fowke KR, et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998;102:1758-1765.
45. Stranford SA, Skumick J, Louria D, et al. Lack of infection in HIV-exposed individuals is associated with a strong CD8 + cell noncytotoxic anti-HIV response. Proc Natl Acad Sci USA 1999; 96:1030-1035.
46. Butera ST, Pisell TL, Limpakarnjanarat K, et al. Production of a novel viral suppressive activity associated with resistance to infection among female sex workers exposed to HIV type 1. AIDS Research and Human Retroviruses 2001;17:735-744.
47. Kashuba ADM, Dyer JR, Kramer LM, et al. Antiretroviral drug concentrations in semen: implications for sexual transmission of HIV-1. Antimicrob Agents Chemother 1999;43:1817-1826.
48. Molla A, Vasavanonda S, Kumar G, et al. Human serum attenuates the activity of protease inhibitors toward wild- type and mutant human immunodeficiency virus. Virology 1998;250: 255-262.
49. Pereira AS, Kashuba AD, Fiscus SA, et al. Nucleoside analogues achieve high concentrations in seminal plasma:relationship between drug concentration and virus burden. J Infect Dis 1999;180:2039-2043.
50. Henry K, Chinnock BJ, Quinn RP, et al. Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA 1988;259:3023-3026.
51. Taylor S, van Heeswijk RP, Hoetelmans RM, et al. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS 2000;14:1979-1984.
52. Reijers MH, van Heeswijk RP, Jurriaans S, et al. The concentrations of D4T, 3TC, nelfinavir (NFV), and saquinavir (SQV) in plasma, cerebrospinal fluid (CSF) and semen. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Jan. 30-Feb. 2, 2000, Abstract 316.
53. Liuzzi G, Chirianni A, Casazza R, et al. Concentration of stavudine in blood an semen from HIV-1 infected patients. AIDS 2000;14(suppl 4):S96-S97.
54. Anderson PL, Noormohamed SE, Henry K, et al. Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection. Pharmacotherapy 2000; 20:917-922.
55. Fletcher CV, Acosta EP, Henry K, et al. Concentration-controlled zidovudine therapy. Clin Pharmacol Ther 1998;54:331-338.
56. Moore KH, Barrett JE, Shaw S, et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 1999;13: 2239-2250.
57. Taylor S, van Heeswijk RP, Hoetelmans RM, et al. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV- 1-infected men. AIDS 2000;14:1979-1984.
58. Reddy S, Kim JD, Eron JJ, et al. Efavirenz (EFV)-Containing Antiretroviral (ARV) Therapy (T) Effectively Reduces HIV RNA in the Seminal Plasma (SP) of HIV-1-Infected Men (M). 8th Conference on Retroviruses and Opportunistic Infections, Chicago, 4-8 Feb 2001, Abstract 750.
59. th Conference on Retroviruses and Opportunistic Infections 2000, San Francisco, CA.
60. Pereira AS, Gerber JG, Smeaton L, et al. The Pharmacokinetics of amprenavir, lamivudine, and zidovudine in the male genital tract of HIV-1-infected men. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, 4-8 Feb 2001, Abstract 749.
61. van Praag RME, Weverling GJ, Portegies P, et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000;14:1187-1194.
62. Taylor S, Raynolds, Drake SM, et al. A pharmacokinetic study of indinavir (IDV) 600 mg bid and ritonavir(RTV) 200 mg bid in plasma and semen of HIV-1 infected men. AIDS 2000; 14(suppl 4):S96.
63. Kim R. Role of P-glycoprotein in CNS and genital tract penetration. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, 4-8 Feb 2001, Abstract S1.
64. Creatsas G, Lolis D, Paveatos M, Kaskarelis D. Gentamicin in the treatment of lower genital tract infections: level of the drug in menses, cervical mucus and vaginal fluid. International Journal of Clinical Pharmacology and Biopharmacy 1979;17:225-227.
65. Pulkkinen MO, Vuento M, Macciocchi A, et al. Distribution of oral nimesulide in female genital tissues. Biopharmaceutics and Drug Disposition 1991;12:113-117.
66. Gerstner GJ, Dalhoff A, Weuta H. Single and multiple dose pharmacokinetics of ciprofloxacin in gynecological tissues. Infection 1988;16(suppl 1):S24-28.
67. Takese Z, Shirafuji U, Maki M, et al. Fundamental studies on aspoxicillin in the field of gynecology. Penetration of the drug into the genital organs and the dead space fluid. Antibacterial activity of the drug. Japanese Journal of Antibiotics 1985;38:1979-2002.
68. Si-Mohamed A, Kazatchkine M, Heard I, et al. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type-I-infected women receiving antiretroviral therapy. Journal of Infectious Diseases 2000;182:112-122.
69. Hoetelmans RM, van Essenberg M, Meenhorst PL, et al. Determination of saquinavir in human plasma, saliva, and cerebrospinal fluid by ion-pair high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography. D, Biomedical Sciences & Applications 1997;698:235-241.
70. van Heeswijk RP, Veldkamp AI, Mulder JW, et al. Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine. Ther Drug Monit 2001;23(3):255-258.
71. Barroso PF, Schechter M, Gupta P, et al. Effect of antiretroviral therapy on HIV shedding in semen. Ann Intern Med 2000;133:280-284.
72. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. AIDS 2000;14:117-111.
73. Vernazza P, Perrin L, Vora S, et al. Increased seminal shedding of HIV during primary infection augment the need for earlier diagnosis and prevention. Abstract 564. San Francisco: Seventh Conference on Retroviruses and Opportunistic Infections, 2000.
74. Pilcher CD, Shugars DC, Fiscus SA, et al. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS 2001;15:837-845.
75. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-1613.
76. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999;341:385-393.
77. Musicco M, Lazzarin A, Nicolosi A, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Arch Intern Med 1994;154:1971-1976.
78. Quinn T, Gray R, Sewankambo N, et al. Therapeutic reductions of HIV viral load to prevent HIV transmission: data from HIV discordant couples; Rakai, Uganda. XIII International AIDS Conference, Durban, South Africa, Abstract vol. 1, Abstract TuPeC3391:412.
79. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000;287: 650-654.
80. Law MG, Prestage G, Grulich, et al. Modelling the effect of combination antiretroviral treatment on HIV incidence. AIDS 2001;15: 1287-1294.
81. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: Implications for prevention of sexual transmission of HIV-1. Lancet 1997;349:1868-1875.
82. Ghys PD, Fransen K, Diallo MO, et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. AIDS 1997;11:F85-F93.
83. Winters AJ, Taylor S, Workman J, et al. Asymptomatic urethritis and detection of HIV- RNA in seminal plasma. Sex Transm Inf 1999;75:261-263.
84. Stolte IG, Dukers NHTM, de Wit JBF, et al. Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAART. Sex Transm Inf 2001;177: 184-186.
85. Brewer TH, Metsch L, Zenilman J. Utilization of a public STD clinic by known HIV positive adults: decreased self reported risk behavior, increased disease incidence. Sex Transm Inf 2001;12(suppl. 2):158. Abstract.
86. Stephenson JM, Imric J, Davis MD, et al. Sexual risk behaviour of HIV-seropositive gay men attending a London outpatient clinic. Int J STD AIDS 2001;12(suppl 2):184, Abstract.
87. Hart GJ, Davis M, Imrie J, et al. If I'm not asked directly then I don't always tell people: disclosure of HIV status to sexual partners by gay men on HAART. Int J STD AIDS 2001; 12(suppl 2):185, Abstract.
88. Scheer S, Chu PL, Klausner JD, et al. Effect of highly active antiretroviral therapy on the diagnoses of sexually transmitted diseases in people with AIDS. Lancet 2001;357:432-435.
89. Eron JJ, Vernazza PL, Johnston DM, et al. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS 1998;12:F181-F189.
90. Mayer KH, Boswell S, Goldstein R, et al. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Clin Infect Dis 1999;28: 1252-1259.
91. Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999;282:1142-1148.
92. Imrie A, Beveridge A, Genn W, et al. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis 1997;175(6):1502-1506.
93. Angarano G, Monno L, Appice A, et al. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts. AIDS 1994;8:1013-1014.
94. Conlon CP, Klenerman P, Edwards A, et al. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis 1994;169: 411-415.
95. Koopman JS, Jacquez JA, Welch GW, et al. The role of early HIV infection in the spread of HIV through populations. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1997;14:249-258.
96. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD. Vigorous HIV-1-specific CD4 + T cell responses associated with control of viremia. Science 1997;278:1447-1450.
97. Anderson RM, May RM. Epidemiologic parameters of HIV transmission. Nature 1988;333: 514-519.
98. Kravcik S, Victor G, Houston S, et al. Effect of antiretroviral therapy and viral load on the perceived risk of HIV transmission and the need for safer sexual practices. Journal of Acquired Immune Deficiency Syndromes 1998;19:124-129.
99. Miller M, Meyer L, Boufassa F, et al. Sexual behavior changes and protease inhibitor therapy. AIDS 2000;14:F33-F39.
100. van der Straten A, Gomez CA, Saul J, et al. Sexual risk behaviors among heterosexual HIV serodiscordant couples in the era of postexposure prevention and viral suppressive therapy. AIDS 2000;14:F47-F54.
101. CDC. Serostatus Approach to Fighting the HIV epidemic (SAFE), www.cdc.gov.
102. Ruiz MS, Gable AR, Kaplan EH, et al., eds. No Time to Lose: Getting More from HIV Prevention. National Academy Press, Washington, DC, 2001.
103. CDC. Management of Possible Sexual, injecting-Drug-Use, or other Nonoccupational Exposure to HIV, including Consideration Related to Antiretroviral therapy Public Health Service Statement. MMWR 1998;47:1-14.
104. CDC. Updated U.S. Public Health Service Guidelines for the Management of Occupational exposure to HBV, HCV, and HIV and recommendations for Postexposure Prophylaxis. MMWR 2001;50:1-42.
105. Cardo DM, Culver DH, Ciesilski CA, et al. A Case-Control study of HIV seroconversion in Health Care Workers after percutaneous exposure. New Engl J Med 1997;337:1485-1490.
106. Jochimsen EM. Failures of zidovudine post exposure prophylaxis. Am J Med 1997;102:52-55.
107. Mofenson LM, McIntyre JA. Advances and research direction in the prevention of mother-to-child HIV-1 transmission. Lancet 2000:335; 2237-2244.
108. Conner EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173-1180.
109. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand:a randomised controlled trial. Lancet 1999;353: 773-780.
110. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. New England Journal of Medicine 2000;343:982-991.
111. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999;353: 781-785.
112. Ditrame ANRS 049 Study Group. 15 month efficacy of maternal oral zidovudine to decrease vertical transmission of HIV-1 in breast fed African Children. Lancet 1999:354:2050-51.
113. Saba J. for the PETRA trial study team. Interim analysis of early efficacy of three short ZDV/3TC combination regimens to prevent mother-to-child transmission of HIV-1: The PETRA Trial. 6th Conference on Retroviruses and Opportunistic Infection Chicago, January-February, 1999 abstr 570.
114. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999:354;795-802.
115. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated Regimens of Zidovudine Prophylaxis and Perinatal Transmission of the Human Immunodeficiency Virus. N Engl J Med 1998: 339;1409-1414.
116. Kahn JO, Martin JN, Roland ME, et al. Feasibility of Postexposure Prophylaxis (PEP) against Human Immunodeficiency Virus Infection after Sexual or Injection Drug Use Exposure: The San Francisco PEP Study. J Infectious Diseases 2001;183:707-714.
117. th Conference on Retroviruses and Opportunistic Infections, Feb. 4-8, 2001. Abstract 225.
118. Benais JP, Miara A, Brion S, et al. Treatment of Sexual Assault: A multicentrique Study in emergency medico-legal units in the Paris Region. Program and abstracts of the XIII International AIDS Conference; July 9-14, 2000; Durban, South Africa. Abstract TuOrC314.
119. Myles JE, Hirozawa A, Katz MH, et al. Post-exposure prophylaxis for HIV after sexual assault. JAMA. 2000;284:1516-1517.
120. Joag SV. Primate models of AIDS. Microbes and Infection. 2000;2:223-229.
121. Black RJ. Animal studies of prophylaxis. American Journal of Medicine 1997;102:39-44.
122. McClure HM, Anderson DC, Ansari AA, et al. Nonhuman primate models for evaluation of AIDS therapy. In AIDS: Anti-HIV Agents, Therapies and Vaccines. Ann NY Acad Sci 1990;616:287-298.
123. Fazely F, Haseltine W, Rodger R, Ruprecht R. Postexposure Chemoprophylaxis with ZDV or ZDV combine with Interferon-α: Failure after Inoculating Rhesus Monkeys with a High Dose of SIV. J AIDS 1991;4:1093-1097.
124. Lundgren B, Ljungdahl S, Bottiger D, et al. Acute infection of cynomolgus monkeys with Simian immunodeficiency virus(SIVsm) as a model to evaluate antiviral compounds. Effects of 3′-azido, 3′-deoxythymidine foscarnet and 2′, 3′-dideoxycytidine. Antiviral Chemistry and Chemotherapy 1990:1:299-306.
125. Bottiger D, Ljungdahl-Stahle E, Oberg B. Treatment of acute SIV infection in cynomolgus monkeys with 2′,3′-dideoxyinosine (ddI) and 2′,3′-Dideoxythymidiene (d4T). Antiviral Chemistry & Chemotherapy 1991;2:257-361.
126. Lundgren B, Bottinger D, Ljungdahl-Stahle E, et al. Antiviral Effects of 3′-Fluorothymidine and 3′-Azidothymidine in Cynomolgus Monkeys Infected with Simian Immunodeficiency Virus. J AIDS;1991:4:489-498.
127. Bottiger D, Putkonen P, Oberg B. Prevention of HIV-2 and SIV infections in cynomolgus macaques by prophylactic treatment with 3′-Fluorothymidine. AIDS research and human retroviruses 1992;8:1235-1238.
128. Martin LN, Murphey-Corb M, Soike KF, et al. Effects of initiation of 3′-azido, 3′-deoxythymidine (Zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. J Infect Dis 1993;168:625-635.
129. Bottiger D, Johansson N, Samuelsson B, et al. Prevention of simian immunodeficiency virus SIMsm, or HIV-2 infection in cynomolgus monkeys by pre and post exposure administration of BEA-005 AIDS 1997;11:157-162.
130. Tsai CC, Follis KE, Grant RF, et al. Effect of dosing frequency on ZDV prophylaxis in Macaques infected with simian immunodeficiency virus. J AIDS 1993;6:1085-1092.
131. Le Grand R, Clayette P, Noack O, et al. An animal model for Antilentiviral therapy: Effect of Zidovudine on Viral Load during Acute infection after exposure of Macaques to Simian Immunodeficiency Virus. AIDS Res Hum Retroviruses 1994;10:1279-1287.
132. Mori K, Yasutomi Y, Shuzo s, et al. Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW-420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection. Journal of Virology 2000;74:5747-5753.
133. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2 phosphonylmethoxypropy]) adenine. Science 1995; 270:1197-1199.
134. Tsai CC, Emau P, Follis KE, et al. Effectiveness of post-inoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998;72:4265-4273.
135. Van Rompay KKA, Otsyula MD, Marthas ML, et al. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimircob Agents Chemother 1995;39:124-131.
136. Ho RJY, Larsen K, Bui T, et al. Suppression of maternal virus load with zidovudine, didanosine, and indinavir combination therapy prevents mother-to-fetus HIV transmission in macaques. J AIDS 2000;25:I40-14.
137. Van Rompay K, Marthas ML, Lifson JD, et al. Administration of 9-[2-(Phosphonomethoxy) propyl]adenine (PMPA) for prevention of perinatal simian Immunodeficiency Virus Infection in Rhesus macaques. AIDS Research and human retroviruses 1998;14:761-773.
138. Van Rompay KK, Berardi CJ, Aguirre NL, et al. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS 199;12:F29-F83.
139. Van Rompay KK, Miller MD, Marthas ML, et al. Prophylactic and therapeulic benefits of short-term 9-[2-(R) Phosphonomethoxy propyl] adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virology 2000;74: 1767-1774.
140. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virology 2000;74:9771-9775.
141. Wyand M, Manson K, Miller N, et al. Prevention of intravaginal transmission of SIV infection in rhesus monkeys using PMPA gel. In: Conference Supplement of the 12th Annual World AIDS Conference, Geneva, 1999, Abstract #11245.
142. Katz MH, Gerberdering JL. The care of persons with recent sexual exposure to HIV. Ann Intern Med 1998;128:306-312.
143. Pinkerton SD, Holtgrave DR, Bloom FR. Postexposure treatment of HIV. N Engl J Med 1997;337:499-501.
144. Pinkerton SD, Holtgrave DR, Bloom FR. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV. AIDS 1998;12:1067-1078.
145. Low-Beer S, Weber AE, Bartholomew K, et al. A reality check: the cost of making post-exposure prophylaxis available to gay and bisexual men at high sexual risk. AIDS 2000;14:325-326.
146. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR 2000;49:1153-1156.
147. Rothenberg RB, Scarlett M, del Rio C, et al. Oral transmission of HIV: a review of the evidence. AIDS 1998;12:2095-2105.
148. Cohen MS, Shugars DC, Fiscus SA. Limits on oral transmission of HIV-1. Lancet 2000;356: 272.
149. th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000 (abstr 473).
150. Page-Shafer K, Shibosk C, Dilley J, et al. Risk of oral transmission of HIV infection and oral sexual behavior among men who exclusively practice oral sex in San Francisco, California. 2001 National HI Prevention Conference, August 12-15, 2001 (abstr 975).
151. Anderson DJ, O'Brien TR, Politch JA, et al. Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. JAMA 1992;267:2769-774.
152. Eron JJ Jr, Smeaton LM, Fiscus SA, et al. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850). Journal of Infectious Diseases 2000;181:1622-1628.
153. Gilliam BL, Dyer JR, Fiscus SA, et al. Effect of reverse transcriptase inhibitor therapy on HIV-1 viral burden in semen. J Acquire. Immune Defic Syndr Hum Retrovirol 1997;15: 54-60.
154. Gupta P, Mellors J, Kingsley L, et al. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol 1997:71:6271-6275.
155. Hamed KA, Winters MA, Holodniy M, et al. Detection of human immunodeficiency type 1 in semen: effects of disease stage and nucleoside therapy. J Infect Dis 1993;167:798-802.
156. Krieger JN, Coombs RW, Collier AC, et al. Recovery of HIV-1 from semen: minimal impact of stage of infection and current antiviral therapy. J Infect Dis 1991;163:386-388.
157. Krieger JN, Coombs RW, Collier AC, et al. Intermittent shedding of human immunodeficiency virus in semen: implications for sexual transmission. J Urol 1995;154:1035-1040.
158. Kroodsma KL, Kozal MJ, Hamed KA, et al. Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. J Infect Dis 1994; 170:1292-1295.
159. Vernazza PL, Gilliam BL, Dyer J, et al. Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 1997;11:987-993.
160. Vernazza PL, Gilliam BL, Flepp M, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997;11:1249-1254.
161. Zhang H, Dornadula G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998;339:1803-1809.
162. Van Rompay KKA, Marthas ML, Ramos RA, et al. Simian Immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3′Azido-3′deoxythymidine prevents SIV infection. Antimicrob Agents Chemother 1992;36:2381-2386.
163. Watson A, McClure J, Ranchalis J, et al. Early postinfection antiviral treatment reduces viral load and prevents CD4 + cell decline in HIV type 2-infected macaques. AIDS Res Hum Retroviruses 1997:13:1375-1381.
164. Vemazza PL, Kashuba A, Cohen MS. Biological correlates of sexual transmission of HIV: practical consequences and potential targets for public health. Reviews in Medical Microbiology 2001;12:131-142.